NEW YORK (GenomeWeb News) – Trilink BioTechnologies said today that it has inked a new licensing agreement with Biofortuna allowing the UK firm to use Trilink's hot start deoxynucleotides for freeze-drying molecular diagnostic kit development and production service.

Biofortuna offers this product to "diagnostic companies looking to develop stabilized molecular diagnostic kits," said Mike Bunce, chief science officer of Biofortuna, in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.